Article · Wikipedia archive · Last revised Jul 21, 2026

XOB

XOB, also known as ASR-6001 or as N-[(4-phenylbutoxy)hexyl]-4-bromo-2,5-dimethoxyphenethylamine, is a serotonin 5-HT2A receptor antagonist and voltage-gated sodium channel (VGSC) blocker of the phenethylamine and 2C families. It is a derivative of 2C-B in which the amine-containing side chain has been extended with the same long group found in salmeterol.

Last revised
Jul 21, 2026
Read time
≈ 1 min
Length
218 w
Citations
6
Source
Wikipedia ↗
XOB
Clinical data
Other namesASR-6001; ASR6001; N-[(4-Phenylbutoxy)hexyl]-4-bromo-2,5-dimethoxyphenethylamine
Drug classSerotonin 5-HT2A receptor antagonist; Voltage-gated sodium channel blocker
ATC code
  • None
Identifiers
  • N-[2-(4-bromo-2,5-dimethoxyphenyl)ethyl]-6-(4-phenylbutoxy)hexan-1-amine
PubChem CID
Chemical and physical data
FormulaC26H38BrNO3
Molar mass492.498 g·mol−1
3D model (JSmol)
  • COC1=CC(=C(C=C1CCNCCCCCCOCCCCC2=CC=CC=C2)OC)Br
  • InChI=1S/C26H38BrNO3/c1-29-25-21-24(27)26(30-2)20-23(25)15-17-28-16-9-3-4-10-18-31-19-11-8-14-22-12-6-5-7-13-22/h5-7,12-13,20-21,28H,3-4,8-11,14-19H2,1-2H3
  • Key:GOUKDEUQBCARRO-UHFFFAOYSA-N

XOB, also known as ASR-6001 or as N-[(4-phenylbutoxy)hexyl]-4-bromo-2,5-dimethoxyphenethylamine, is a serotonin 5-HT2A receptor antagonist and voltage-gated sodium channel (VGSC) blocker of the phenethylamine and 2C families.1 It is a derivative of 2C-B in which the amine-containing side chain has been extended with the same long group found in salmeterol.1

The drug is of relatively low potency as a serotonin 5-HT2A receptor antagonist.1 It shows modest selectivity for the serotonin 5-HT2A receptor over the serotonin 5-HT2B and 5-HT2C receptors.1 XOB was accidentally found to have local anesthetic properties upon contact with human skin, which led to the elucidation of its sodium channel-blocking activity.1

XOB was developed in part by researchers at the Alexander Shulgin Research Institute (ASRI).1

See also

See also

References

References

  1. Denomme N, Hernandez CC, Bock HA, Ohana RF, Bakshi S, Sherwood AM, McCorvy JD, Daley PF, Callaway WB, Hull JM, Alt A, Isom LL, Cozzi NV (July 2024). "N-(4-Bromo-2,5-Dimethoxyphenethyl)-6-(4-Phenylbutoxy)Hexan-1-Amine (XOB): A Novel Phenylalkylamine Antagonist of Serotonin 2A Receptors and Voltage-Gated Sodium Channels" (PDF). Mol Pharmacol. 106 (2): 92–106. doi:10.1124/molpharm.123.000837. PMID 38821630.
External links